Maze Therapeutics (MAZE) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maze Therapeutics (MAZE) has outperformed Mesoblast (MESO) over the past year, losing 5.8% versus a loss of 22.9%. Mesoblast is the larger company by market cap ($1.81 billion vs $1.46 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAZE | MESO |
|---|---|---|
| Share price | $26.25 | $13.94 |
| Market cap | $1.46B | $1.81B |
| 1-day change | -0.68% | +2.42% |
| YTD return | -36.64% | -22.73% |
| 1-year return | -5.78% | -22.94% |
| 5-year return | — | +22.71% |
| Forward P/E | — | 30.64 |
| EPS (TTM) | $-2.46 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $53.65 | $21.50 |
| 52-week low | $21.95 | $13.05 |
| Distance from 52-week high | -51.07% | -35.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +134.29% | +165.42% |
| Average volume | 556.08K | 236.60K |
| Shares outstanding | 55.55M | 129.85M |
| Employees | 141 | 108 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAZE has outperformed MESO by 17.2 percentage points over the past year.
- The two companies sit in different sectors: Maze Therapeutics in Healthcare and Mesoblast in Health Care.
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Healthcare · Biotechnology · 141 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
MAZE vs MESO FAQ
Which is bigger, Maze Therapeutics or Mesoblast?
Mesoblast (MESO) is larger, with a market capitalization of $1.81B compared with $1.46B for Maze Therapeutics (MAZE).
Which stock has performed better over the past year, MAZE or MESO?
MAZE returned -5.78% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Maze Therapeutics and Mesoblast in the same industry?
No. Maze Therapeutics is in the Healthcare sector, while Mesoblast is in Health Care.